Vendor, Haifa, ISR, part of Pluristem Therapeutics Inc.
Pluri Biotech Ltd.
UEI MEDCUE4LMZE6, CAGE 3704A
1 award and $1,416,470 obligated between June 3, 2024 and April 15, 2025, 100% under full and open competition, against 16.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $1,416,470 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93023C00012Definitive Contract, June 3, 2024, Full and Open Competition, 16 offers | National Institutes of Health NiaidNational Institutes of Health | Development of Plx-R18 Cell Therapy as a Countermeasure for Hematopoietic Acute Radiation SyndromeNAICS 541714, PSC AN12 | $1,416,470 |
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 2 across 1 awards